Prevalence and related factors of anemia in HAART-naive HIV positive patients at Gondar University Hospital, Northwest Ethiopia

Getachew Ferede* and Yitayih Wondimeneh

Abstract

Background: Anaemia is a common complication of infection with the human immunodeficiency virus (HIV) and may have various causes. The aim of this study was to determine the prevalence and related factors of anemia in HAART-naive HIV positive patients.

Methods: A retrospective study was conducted on HAART naive HIV positive patients at the Gondar University Hospital between September 2011 and August 2012. Socio-demographic and immunohematological (hemoglobin and CD4+ T cells) data were collected carefully from the existing ART logbook and patient follow up cards. Anaemia was defined according to the WHO criteria.

Results: The overall prevalence of anaemia was 138 (35%). Female HAART naive HIV positive patients had significantly (P < 0.05) higher prevalence of anaemia than males (62% Vs 38%). The prevalence of anaemia at different CD4 level was; 6 (4%) with CD4 count greater than 500 cells/μL, 18 (13%) with a CD4 count of 350–500 cells/μL, 37 (27%) with a CD4 count of 200–349 cells/μL, 44 (32%) with a CD4 count of 100–199 cells/μL, 14 (10%) with a CD4 count of 50–99 and 19 (14%) with CD4 count of less than 50 cells/μL.

Conclusions: Our findings showed that one-third of HAART naïve HIV positive patients were anaemic and the increase in prevalence of anaemia with decreased CD4 cell count was statistically significant. Therefore, early diagnosis and treatment of anaemia in these patients are essential.

Keywords: Anaemia, HIV, HAART-naive, CD4 count

Background

Human immunodeficiency virus (HIV) infection is frequently associated with hematologic abnormalities such as anaemia. This association may have many causes [1,2]. A systematic review of these abnormalities has shown that the prevalence of anaemia in HIV positive patients ranges from 20-80% and is associated with faster disease progression and mortality [3]. This makes it more common than thrombocytopenia or leucopenia in patients with AIDS [4]. In established HIV infection, lower haemoglobin levels have been shown to correlate with decreasing CD4+ cell counts [5] and many studies have found an association between anaemia during established infection and a faster progression to AIDS and death [6,7]. Therefore, interventions to prevent anaemia may lead to improved health and survival potential of HIV-infected persons [8].

Anaemia has been reported to influence the natural history of HIV disease by increasing the rate of disease progression and mortality in both developed and developing countries [1]. Mocroft et al. have demonstrated that severe anaemia is linked with faster rate of HIV disease progression. They have also shown that anaemia is a strong predictor of death [9]. The consequences of untreated anemia may lead to multisystem disabling symptoms and fatigue, exhaustion, increased risk of HIV dementia, poor quality of life and possibly even exacerbates poverty in communities with a high HIV prevalence [10]. On the other hand, survival time in HIV-infected persons may be enhanced after recovery from anemia [11].
Several observational studies have also reported a higher mortality in HIV infected patients from low haemoglobin levels even after adjusting for CD4 cell count and viral load [3,7]. The etiology of anaemia in HIV infection is multifactorial and typically the anaemia may result from low production of red blood cells, increased RBC destruction, or ineffective RBC production [12] and frequently the laboratory features are compatible with anaemia of chronic disease with a low reticulocyte count, normocytic and normochromic red blood cells with normal iron stores and cytokine mediated poor erythropoietin response [13,14].

Other mechanisms for HIV-associated anemia, although uncommon, include vitamin B₁₂ deficiency and the autoimmune destruction of erythrocytes [15]. Direct infection of marrow precursor cells [16] has been hypothesized, but not proven. However, studies from developed countries suggest that the use of highly active antiretroviral therapy (HAART) is associated with an increase in haemoglobin concentrations and a decrease in the prevalence of anaemia. Amelioration of HIV-related anaemia with HAART has several benefits including improvements in functional status, energy levels and fatigue and overall improvement in quality of life [16].

However, sufficient treatment of anaemia is not always considered in developing countries. This is because most notice is given to HIV infection and the frequent complications such as opportunistic infections [17]. Moreover, there is wide variation in the prevalence of anaemia among HIV/AIDS patients in different studies all over the world and paucity information on the prevalence of anaemia among HIV patients in Ethiopia. This study therefore seeks to evaluate the prevalence of anaemia and the related factors among HAART-naïve HIV positive patients at different age groups, gender and CD4 levels.

Methods

A retrospective study of HAART naïve HIV positive patients was conducted at Gondar University Hospital, Northwest Ethiopia, between September 2011 and August 2012. Our study participants were adult (18 years or above) HAART naïve HIV positive individuals. HIV positive patients who were on antiretroviral therapy and pregnant women were excluded. Pre-ART HIV patients who were on medication such as antibiotics, vitamin supplements and tuberculosis treatments were also excluded from the study.

Participant’s socio-demographic variables, history of prophylaxis taken and hematological (hemoglobin) and immunological (CD4+ T cells) values were carefully extracted from ART log book and patients follow up cards. Absolute counts of CD4 lymphocytes were assayed using the BD FACSCOUNT system (Becton Dickenson and Company, California, USA). Haematological parameters such as haemoglobin (Hb) were determined using the automated blood analyzer Cell-Dyn 1800 (Abott Laboratories Diagnostics Division, USA).

Anaemia was defined according to the WHO criteria [18]. For males, anaemia was defined as haemoglobin concentration (Hb) less than 13 g/dl, while for females; the value is less than 12 g/dl. Mild anaemia was defined as a haemoglobin level of 8-13 g/dl for men and 8-12 g/dl for women. Severe anaemia was defined as a haemoglobin level of less than 8 g/dl for both males and females.

Data were entered and analyzed by using SPSS version 16. Descriptive statistics (minimum, maximum, mean and standard deviation) were determined for continuous variables in the course of analysis. Proportions and percentages were calculated for categorical variables. For all statistical comparisons of the groups, the Pearson Chi-square test was used and P-value < 0.05 was considered as statistically significant.

Ethical clearance was obtained from the Institutional Ethical Review Board of University of Gondar. Permission for the conduct of the study was also obtained from the University Hospital.

Results

A total of 420 HAART naïve HIV positive patients’ chart were reviewed but 20 of them were excluded from the

| Table 1 Socio-demographic characteristics of HAART naïve HIV positive patients at Gondar University Hospital, Northwest Ethiopia, 2012 |
|---------------------------------------------------------------|
| **Variables** | **Frequency** | **Percentage (%)** |
|----------------|--------------|-------------------|
| **Age (years)** |              |                   |
| 18-29          | 128          | 32                |
| 30-39          | 168          | 41.8              |
| 40-49          | 78           | 19.5              |
| 50 & above     | 27           | 6.8               |
| **Sex**        |              |                   |
| Male           | 122          | 30.5              |
| Female         | 278          | 69.5              |
| **Residence**  |              |                   |
| Urban          | 335          | 83.8              |
| Rural          | 65           | 16.2              |
| **Religion**   |              |                   |
| Christian      | 368          | 91.8              |
| Muslim         | 31           | 7.7               |
| Others         | 2            | 0.5               |
| **Marital status** |          |                   |
| Married        | 200          | 50                |
| Single         | 75           | 18.8              |
| Divorced       | 82           | 20.5              |
| Widowed        | 43           | 10.8              |
study due to co-infection, opportunistic infection, pregnancy and those who were on medication (antibiotics and vitamin supplements). The overall prevalence of anaemia was 138 (35%) and majority of patients had mild to moderate anaemia. Mild to moderate anaemia and severe anaemia occurred in 128 (32%) and 10 (3%) patients, respectively. Female HAART naive HIV positive patients had significantly higher prevalence of anaemia than males (62% Vs 38%) (P<0.05) (Table 1, 2 and 3).

Hemoglobin levels of the study participants were between 4.7 and 18 g/dL with the mean of 12.6 ± 2.0 g/dL. The minimum CD4 count was 6 cells/μL, and the maximum was 1193 cells/μL. The mean CD4 count was 288±190.2 cells/μL. In this study, majority of the anaemic cases 62 (45%) were observed in the age group of 30–39 years. However, the difference was not statistically significant (Table 4).

In this study, the prevalence of anaemia was showed statistical significance (P<0.05) with CD4 T-cell count. We found that 6 (4%) with CD4 count greater than 500 cells/μL, 18 (13%) with a CD4 count of 350–500 cells/μL, 37 (27%) with a CD4 count of 200–349 cells/μL, 44 (32%) with a CD4 count of 100–199 cells/μL, 14 (10%) with a CD4 count of 50–99 and 19 (14%), with CD4 count of less than 50 cells/μL (Table 5).

### Discussion

Anaemia is frequently encountered aberration in HIV patients [19] which may be clinically important. Multifactorial causes of anaemia may complicate its original cause and/or its suitable treatment [20]. The prevalence of anaemia in this study was 138 out of 400 (35%) which is in agreement with study of Mildvan et al., [21] and Levine et al., [22]. However, low prevalence was reported by Semba et al., who concluded that anaemia was in 28.1% of HIV patients [23]. In addition Mata-Marin et al., [24] and Akinsegun et al., [25] reported 20% and 24.2% prevalence of anaemia among HAART naive HIV patients respectively, which was lower than our study.

In this study, females had significantly higher prevalence of anaemia than male patients 85 (62%) Vs 53 (38%) (p<0.05), which is in agreement with findings of Owiredu et al., [26] and Nadler et al., [27]. Moreover, mostly female gender has been reported as a risk factor for anaemia among HIV patients [27]. However, the finding in this study was in contrast to the findings of a study conducted in Nigeria [28].

In this study, as the immunity of a patient decreases, anaemia was more prevalent in patients rather than in HIV positive patients who have relatively high CD4 count. For example, the prevalence of anaemia was highest among patients who had a CD4 lymphocyte count of 100–199 cells/μL and lowest among patients with a CD4 count > 500 cells/μL. The increase in prevalence of anaemia with decreased CD4 cell count was statistically significant (P < 0.05). Mostly, prevalence of anaemia is higher among the study participants who have low CD4 count. This finding is consistent with the results of Levine et al., [22] and Volberding et al., [29] who reported that more severe levels of anaemia are found among HIV positive patients presenting with low CD4 counts.

The pathogenesis of HIV-related anaemia is indistinct and is possible to be multifactorial in nature [1,30,31]. Possible causes are bleeding (gastrointestinal malignancy/severe infection), insufficient dietary intake (vitamins such as cobalamin and folate, iron, and general malnutrition), haemolytic anaemia (i.e. malignancies, infections, splenomegaly, immune dysfunction), changes in

### Table 2: Prevalence of anaemia among HAART naive HIV positive patients at Gondar University Hospital, Northwest Ethiopia, 2012

| Degree of anaemia     | Frequency | Percentage (%) |
|-----------------------|-----------|----------------|
| Normal                | 262       | 65             |
| Mild to moderate anemia | 128      | 32             |
| Severe anemia         | 10        | 3              |
| Total                 | 400       | 100            |

### Table 3: Prevalence of anaemia by gender among HAART naive HIV positive patients at Gondar University Hospital, Northwest Ethiopia, 2012

| Sex         | Frequency of anaemia | Percentage (%) | P – value |
|-------------|----------------------|----------------|-----------|
| Male        | 53                   | 38             | 0.013     |
| Female      | 85                   | 62             |           |

### Table 4: Relationship between age groups and anaemia among HAART naive HIV positive patients at Gondar University Hospital, Northwest Ethiopia, 2012

| Age group | Frequency of anaemia | Percentage (%) | P – value |
|-----------|----------------------|----------------|-----------|
| 18-29     | 38                   | 28             | 0.117     |
| 30-39     | 62                   | 45             |           |
| 40-49     | 24                   | 17             |           |
| 50 & above | 14               | 10             |           |

### Table 5: Relationship between varying degrees of CD4 count and anaemia among HAART naive HIV positive patients at Gondar University Hospital, Northwest Ethiopia, 2012

| CD4 count | Frequency of anaemia | Percentage (%) | P – value |
|-----------|----------------------|----------------|-----------|
| >500      | 6                    | 4              | 0.001     |
| 350-500   | 18                   | 13             |           |
| 200-349   | 37                   | 27             |           |
| 100-199   | 44                   | 32             |           |
| 50-99     | 14                   | 10             |           |
| <50       | 19                   | 14             |           |
erythropoietin synthesis and/or bone marrow suppression. Suppression of the bone marrow in HIV-infected patients may be initiated in several ways. These include an action of HIV itself (infection of the progenitor of the red blood cell synthesis in late-stage disease), the use of antiretroviral drugs (primarily zidovudine), direct pathogenic involvement of the bone marrow (malignant lymphoma, atypical mycobacteriosis), prophylactic or therapeutic treatment against opportunistic diseases or malignancies which may suppress red blood cell production [23,32], however since the HIV positive patients in this study were HAART-naive and also devoid of coinfection with opportunistic diseases, the anaemia could be associated with the low CD4 count, which concur with other studies [33,34].

To the best of our knowledge, this is the first study in Ethiopia to determine prevalence of anaemia in HIV HAART-naive infected patients. However, this study had limitations such as the inability to estimate erythropoietin levels and viral load. In addition, this study did not include HIV infected patients who were on HAART.

Further longitudinal studies should be conducted to develop interventions aimed at reducing the prevalence of anaemia in HIV infected patients. Moreover, studies on serum iron, ferritin, and total iron binding capacity, folate, cobalamin level and bone marrow could give more information on the aetiology of anaemia in HIV infected individuals. These limitations notwithstanding, the results of this study area true reflection of the circumstances of the study participants and thus this study could serve as a reference for additional recommendations to improve care of HIV infected persons and a step for further studies on the pathophysiology of HIV associated anaemia in Ethiopia.

Conclusions

In conclusion, our findings showed that one-third of HAART naive HIV positive patients in Northwest Ethiopia are anaemic and the increase in prevalence of anaemia with decreased CD4 cell count was statistically significant. Sex variation in the prevalence of anaemia was observed with significant higher prevalence of anaemia observed among females. Therefore, early diagnosis and treatment of anaemia is essential in these patients.

Competing interests

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Authors’ contributions

GF: Participated in conception and design of the study, data collection, analysis and interpretations of the findings, drafting the manuscript and write up. YW: Participated in conception and design of the study, data collection, analysis and interpretations of the findings, reviewed the manuscript. Both authors read and approved the final manuscript.

Acknowledgements

The authors wish to acknowledge Gondar University Hospital staffs for facilitating the data collection.

Received: 21 September 2012 Accepted: 7 August 2013
Published: 9 August 2013

References

1. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW: Epidemiology of anaemia in human immunodeficiency virus (HIV)-infected persons: results from the multisite adult and adolescent spectrum of HIV disease surveillance project. Blood 1998, 91:301–308.
2. Shah I, Murthy AK: Aplastic anemia in an HIV infected child. Indian J Pediatr 2005, 72:359–361.
3. Belperio PS, Rhee DC: Prevalence and outcomes of anaemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 2004, 116:27–43.
4. Atti.li S, Singh V, Rai M, Varma D, AK G: Hematological profile of HIV patients in relation to immune status - a hospital-based cohort from Vanarasi, North India. Turk J Hematol 2008, 25:13–19.
5. Savarino A, Pescammona GP, Boelaert JR: Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences. Cell Biochem Funct 1999, 17:279–287.
6. Lau B, Gangue SJ, Phair JP, Riddler SA, Detels R, et al: Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection. J Acquir Immune Defic Syndr 2005, 39:620–625.
7. Lundgren JD, Mocroft A: Anemia and survival in human immunodeficiency virus. Clin Inf Dis 2003, 37:297–303.
8. Doukas MA: Human immunodeficiency virus associated anemia. Med Clin North Am 1992, 76:699.
9. Mocroft A, Kirk O, Barton SE, Dietrich M, Proroca R, Colebunders R, Pradler M, D’Amminio Monforte A, Ledergerber B, Lundgren JD: Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999, 13:943–950.
10. Sembda RD, Martin BK, Kempen JH, Thorne JE, Wu AW: The impact of anaemia on energy and physical functioning in individuals with AIDS. Arch Intern Med 2005, 165:2229–2236.
11. Sembda RD: Iron-deficiency anaemia and the cycle of poverty among human immunodeficiency virus-infected women in the inner city. Clin Infect Dis 2003, 37:105–111.
12. Evans RH, Saccadini DT: Haematological aspects of HIV infection. Baillieres Best Pract Res Clin Haematol 2000, 13:215–230.
13. Spivak JL: The blood in systemic disorders. Lancet 2000, 355:1707–12.
14. Kreuzer KA, Rockstroh JK, Jelkmann W, Spengler U, Sauerbruch T, et al: Inadequate erythropoietin response to anemia in HIV patients: relationship to serum levels of tumor necrosis factor-alpha, interleukin-6 and their soluble receptors. Br J Haematol 1997, 96:235–9.
15. Onyekachi I: Maximizing response to erythropoietin in treating HIV-associated anemia. Cleve Clin J Med 2001, 68:643–648.
16. Miller MF, Humphrey JH, IIIF PJ, Malaba LC, Mbuya NV, Stoltzfus RJ: Neonatal erythropoiesis and subsequent anemia in HIV-positive and HIV-negative Zimbabwean babies during the first year of life: a longitudinal study. BMC Infect Dis 2006, 6:1.
17. Florence M, Jean Bosco G, Joshua M, Joris D, Jan P: Anemia in Human Immunodeficiency Virus–Infected and Uninfected Women in Rwanda. Am J Trap Med Hyg 2011, 84:456–460.
18. Izsak GJ, Westendorp RLG, Knoks DL: The definition of anemia in older persons. JAMA 1999, 281:1714–1717.
19. Volberding P: The impact of anaemia on quality of life in human immunodeficiency virus infected patients. Clin Infect Dis 2002, 185:110–114.
20. Kreuzer KA, Rockstroh JK: Pathogenesis and pathophysiology of anaemia in HIV infection. Ann Hematol 1997, 75:179–87.
21. Mldovan D, Creagh T, Leitz G: Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients: findings of the Anemia Prevalence Study. Curr Med Res Opin 2007, 23:343–55.
22. Levine AM, Berhane K, Masri-Lavine L, et al: Prevalence and correlates of anaemia in a large cohort of HIV-infected women: Women’s Interagency HIV Study. J Acquir Immune Defic Syndr 2001, 26:26–35.
23. Sembra RD, Shah N, Klein RS, et al: Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 2003, 34:260–6.
24. Mata-Marin JA, Gaytan-Martinez JE, Martinez-Martinez RE, Arroyo-Anduiza CI, Fuentes-Allen JL, Casarrubias-Ramirez M: Risk factors and correlates for anemia in HIV treatment-naïve infected patients: A cross-sectional analytical study. BMC Res Notes 2010, 3:230.

25. Akinsegun A, Olajumoke O, Titilope A, Adewunmi A, Owolabi D, Mobolaji D, Idris D, Alaba A, Oshunkulu V: Hematologic Abnormalities in Treatment-Naïve HIV Patients. Infect Dis 2010, 3:45–49.

26. Owiredu WK, Quaye L, Arndu N, Addai-Mensah O: Prevalence of anaemia and immunological markers among Ghanaian HAART-naïve HIV-patients and those on HAART. Afr Health Sci 2011, 11:2–15.

27. Nadler JP, Wills TS, Somboonwitt C, Vincent A, Lietz G, Marino K, Naik E, Powers S, Khan N, Almyroudis N, Laatz B: Anemia prevalence among HIV patients: antiretroviral therapy and other risk factors. Antivir Ther 2003, 8:1.

28. Omoregie R, Omokaro EU, Palmer O, Ogefe HO, Egbeobuawaye A, AdegbeJE, Osakue SJ, Ihereje V: Prevalence of anaemia among HIV-infected patients in Benin City, Nigeria. Tanzan J Health Res 2009, 11:1.

29. Volberding PA, Dieterich D, Mildvan D, Mitsuyasu R, Saag M: Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis 2004, 39:1088–9.

30. Coyle TE: Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med clin north am 1997, 81:449–470.

31. Hambleton J: Hematologic complications of HIV infection. Oncology 1996, 10:671–680.

32. Walker RE, Parker RJ, Kovacs JA, et al: Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi's sarcoma treated with zidovudine. Ann Intern Med 1988, 108:372–6.

33. Marieke JVDW, Birgit H, et al: Prevalence, incidence and risk factors of anaemia in HIV-positive and HIV-negative drug users. Addiction 2000, 95:383–392.

34. Dikshit B, Wanchu A, Sachdeva RK, et al: Profile of Hematological Abnormalities in Indian HIV infected Individuals. BMC Blood disorder 2009, 9:5.

Cite this article as: Ferede and Wondimeneh: Prevalence and related factors of anemia in HAART-naïve HIV positive patients at Gondar University Hospital, Northwest Ethiopia. BMC Hematology 2013 13:8.